Longeveron Inc. (LGVN)
NASDAQ: LGVN · IEX Real-Time Price · USD
1.88
-0.07 (-3.59%)
At close: Nov 27, 2023, 4:00 PM
1.98
+0.10 (5.32%)
After-hours: Nov 27, 2023, 4:53 PM EST
Company Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan.
The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty.
The company was incorporated in 2014 and is headquartered in Miami, Florida.
Longeveron Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Feb 12, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Mohamed Wa'el Ahmed Hashad |
Contact Details
Address: 1951 Nw 7th Avenue, Suite 520 Miami, Florida 33136 United States | |
| Phone | 305-302-7158 |
| Website | longeveron.com |
Stock Details
| Ticker Symbol | LGVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001721484 |
| CUSIP Number | 54303L104 |
| ISIN Number | US54303L1044 |
| Employer ID | 47-2174146 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer and Chairman |
| James Clavijo CPA | Chief Financial Officer and Treasurer |
| Paul T. Lehr J.D. | International Executive Director, General Counsel and Secretary |
| Dr. Kwan-Hong Min M.D., Ph.D. | Chief Medical Officer and Interim Chief Executive Officer |
| Dr. Dan Gincel Ph.D. | Senior Vice President of Strategic Collaborations and Scientific Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 21, 2023 | EFFECT | Notice of Effectiveness |
| Nov 15, 2023 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Nov 14, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 14, 2023 | DEF 14A | Other definitive proxy statements |
| Nov 9, 2023 | 10-Q | Quarterly Report |
| Nov 2, 2023 | PRE 14A | Other preliminary proxy statements |
| Oct 24, 2023 | D | Notice of Exempt Offering of Securities |
| Oct 13, 2023 | 8-K | Current Report |
| Oct 13, 2023 | 424B5 | Filing |
| Oct 5, 2023 | 8-K | Current Report |